On August 3, 2026 Onoctelic Therapeutics Inc. (OTCQB:OTLC), based in Agoura Hills, focused on Oncology Drug Development, reported that Dr. Vuong Trieu, CEO and Chairman, will present live at the OTCQB Virtual Investor Conference hosted by VirtualInvestorConferences.com, on August 6th, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
DATE: August 6th
TIME: 2:30 PM ET
REGISTER HERE
Schedule 1×1 meetings here.
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com.
Recent Company Highlights
Phase 1b IV Everolimus (Sapu003) advanced to the next dose cohort following an independent Safety Review Committee recommendation.
European clinical expansion initiated, adding new international study sites.
Two peer-reviewed publications validated the Deciparticle platform and its clinical translation.
Clinical-stage manufacturing established with scalable cGMP production of Deciparticle formulations.
AI platform expanded through PDAOAI and pharmaceutical robotics initiatives integrating drug discovery with GMP manufacturing.
Multiple technology platforms progressing simultaneously, including clinical oncology, AI drug discovery, robotics, and nanomedicine.
(Press release, Oncotelic, AUG 3, 2026, View Source [SID1234669632])